FreeCME

Networks in Neurology: Insights From a Collaborative CME Experience With Practicing Clinicians Regarding New Agents and Strategies for Multiple Sclerosis

CME: 0.75

November 23, 2021
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

This activity is designed to meet the educational needs of multiple sclerosis specialists, general neurologists, advanced practice neurology professionals, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Program Overview

Multiple sclerosis (MS) management has been evolving at a staggering rate for the past two decades, with nearly a third of the 21 available disease modifying therapies (DMTs) receiving their FDA approvals in just the past few years. To assist practitioners in parsing out the rationale for and clinical utitity of these and other late-stage agents, Efficient surveyed five renowned MS specialists regarding their perspectives on these advances. These results formed the base material for a CME initiative in which those same experts led small groups of clinicians in an eight-week learning experience. The groups participated in a variety of activities including self-study, live discussions, group tasks, and assessments. This activity highlights the most important elements that emerged across the experience including key strategies from experts and insights into where participants are truly struggling that likely resonate with other clinicians.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the limitations associated with the use of historical S1P receptor modulators and fumarates and how novel formulations address these challenges to determine the appropriate role and patient selection for these agents in clinical practice.
  • Discuss the rationale for, experience with, and unique features of agents with novel mechanisms of action and alternative anti-CD20 formulations to help guide their optimal utilization across patients with varied presentations of MS.
  • Evaluate published research with and ongoing Phase 3 evaluation of rising BTK inhibitors to discern the potential future role of these agents in the long-term care of patients with MS.

Post a comment to this article